Chronos Archive seal
The Human Record

Sun Yat-sen

Case HR-ET016 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
November 12, 1866 – March 12, 1925
Synthetic DOB
1968-11-12
Index visit
2026-05-04 at age 57
Synthetic MRN
HR-ET016-SYN

Teaching objective: Primary care for a 57-year-old physician by training, now a political leader, who presents with a right upper quadrant mass and weight loss: the work-up of a solid liver mass (multiphase imaging, alpha-fetoprotein, CA 19-9 and CEA, hepatitis B and C serology, liver function with Child-Pugh and ALBI scoring, and biopsy because a mass in a non-cirrhotic liver cannot be diagnosed by imaging alone, following the AASLD 2023 guidance), the finding of a gallbladder adenocarcinoma invading the liver rather than a primary liver cancer (mirroring the historical conflict between the operative and autopsy findings), staging laparoscopy and the multidisciplinary tumor board on the NCCN biliary tract cancers guideline, first-line gemcitabine, cisplatin and durvalumab with its monitoring, hepatitis B reactivation monitoring in resolved infection, early specialist palliative care, and the care of a physician as a patient.

Historical timeline

DateEventClaims
November 12, 1866Born in Cuiheng Village.CLM-0001
About 1879 (age thirteen)Began his studies in Honolulu.CLM-0002
1886Began studying Western medicine at the Boji Hospital in Guangzhou.CLM-0003
1887Entered the College of Medicine for Chinese in Hong Kong.CLM-0003
July 23, 1892Received his medical diploma at the college's first graduation ceremony.CLM-0003
1893Moved his medical practice from Macau to Guangzhou.CLM-0004
1894Founded the China Revival Society in Honolulu; left medicine for politics.CLM-0004, CLM-0005
1905Founded the Chinese Revolutionary League in Tokyo.CLM-0005
January 1, 1912Became Provisional President of the Republic of China in Nanjing.CLM-0005
January 1924Presided over the First National Congress of the Kuomintang in Guangzhou.CLM-0005
December 31, 1924Arrived in Beijing in poor health.CLM-0006
January 26, 1925Admitted to the Peking Union Medical College Hospital; exploratory laparotomy found carcinoma involving the liver.CLM-0007, CLM-0008, CLM-0010
February 18, 1925Left the hospital against advice.CLM-0008
March 12, 1925Died in Beijing.CLM-0009, CLM-0010
March 13, 1925Limited autopsy reported adenocarcinoma of the gallbladder with spread to the liver and beyond.CLM-0011

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Sun Yat-sen was born on November 12, 1866, into an ordinary farming family in Cuiheng Village. He was called Dixiang in childhood and also had the names Mingwen, Deming and Rixin; the name Yat-sen came into use while he was in Japan.
The birth date used for the synthetic date of birth.
confirmed Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports
D He went to a private school at nine, studied in Honolulu from the age of thirteen, and returned home at seventeen.
Social history.
confirmed Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports
D He began studying Western medicine at the Boji Hospital in Guangzhou in 1886 and in 1887 transferred to the College of Medicine for Chinese in Hong Kong, as one of its twelve students; his teachers included Patrick Manson. He was one of two students who passed the graduation examination in 1892 and received his diploma at the college's first graduation ceremony on July 23, 1892.
The anchor for the modern episode's physician-as-patient theme.
confirmed Chow YYN. From medicine to politics (Dr Sun Yat-sen Oration) supports
Sun Yat-sen chronology supports
D After graduating he practiced medicine in Macau, first at the Kiang Wu Hospital and then in a dispensary of his own, and then in Guangzhou, opening pharmacies that offered Chinese and Western medicines; about two years after graduating he gave up medicine for politics.
He practiced for about two years; the modern episode treats him as a physician by training who left practice decades ago.
confirmed Chow YYN. From medicine to politics (Dr Sun Yat-sen Oration) supports
Sun Yat-sen chronology supports
D In 1894 he founded the China Revival Society in Honolulu; in 1905 he founded the Chinese Revolutionary League in Tokyo; on New Year's Day 1912 he became Provisional President of the Republic of China in Nanjing; and in January 1924 he presided over the First National Congress of the Kuomintang in Guangzhou.
Social history: the anchor for the modern work as the leader of a political organization.
confirmed Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports
Sun Yat-sen chronology supports
D In the autumn of 1924, after the Beijing Coup, he was invited to Beijing to discuss state affairs, and he arrived in Beijing in poor health on the last day of 1924.
After the true-frame episode; history only.
confirmed Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports
Liu Ruiheng supports
D Several months before his operation in January 1925 a mass had been noted in his right upper abdomen and was thought to be his liver; it grew larger shortly before surgery. At the preoperative examination he had no jaundice and not much loss of weight.
The anchor for the modern presenting problem, a right upper quadrant mass. The month the mass was first noted is not recorded.
probable Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death supports
D He was admitted to the Peking Union Medical College Hospital on January 26, 1925, too ill to eat, and had an exploratory laparotomy that day by Adrian S. Taylor, the head of surgery, which found extensive involvement of the liver by carcinoma. He was treated with radium for the rest of his stay, left the hospital against advice on February 18, 1925, and was then treated by old-style Chinese doctors while his condition declined.
History only; after the true-frame episode.
confirmed Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death supports
Liu Ruiheng supports
D He died in Beijing on March 12, 1925.
History only.
confirmed Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death supports
Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports
Sun Yat-sen chronology supports
R His fatal illness has long been described as liver cancer, the diagnosis taken from the findings at the laparotomy; the museum at his birthplace states that he died of liver cancer.
Recorded as the traditional account; a later review of the autopsy report disputes a primary liver cancer (CLM-0011).
disputed Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography supports
Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death disputes
R A limited autopsy at the Peking Union Medical College Hospital on March 13, 1925, by James R. Cash, reported adenocarcinoma of the gallbladder with obstruction of the cystic duct, direct extension to the liver and diaphragm, and metastases to the lungs, peritoneum, ileum and colon, with healed cholecystitis, gallstones, generalized arteriosclerosis, healed calcified tuberculosis of the lungs, emphysema, ascites and roundworm infestation. A 2016 review concludes that gallbladder adenocarcinoma, not a primary liver cancer, caused his death.
The anchor for the modern diagnosis: a gallbladder adenocarcinoma that invades the liver and presents as a liver mass. The review rests on the autopsy report; the original slides were not re-examined in the fetched source.
probable Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged resolved confirmed active CLM-0007
S Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma active confirmed both_with_link CLM-0007, CLM-0008, CLM-0010, CLM-0011
S Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored active confirmed active
S Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectable active confirmed both_with_link CLM-0011
S Acute viral upper respiratory infection on day 10 of cycle 5 of chemoimmunotherapy: sore throat, runny nose and dry cough for three days, afebrile, with a neutrophil count of 1.6 x10^3/uL; rapid tests for SARS-CoV-2 and influenza negative; no sign of pneumonia or pneumonitis; resolved resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-05-04 Leukocytes [#/volume] in Blood by Automated count 7.9 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-05-04 Hemoglobin [Mass/volume] in Blood 12.6 g/dL (low)
Reference 13.2-17.1 g/dL
http://loinc.org · 718-7
S 2026-05-04 Platelets [#/volume] in Blood by Automated count 342 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-05-04 Sodium [Moles/volume] in Serum or Plasma 137 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-05-04 Potassium [Moles/volume] in Serum or Plasma 4.2 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-05-04 Creatinine [Mass/volume] in Serum or Plasma 0.86 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-05-04 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-05-04 Glucose [Mass/volume] in Serum or Plasma 98 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-05-04 Albumin [Mass/volume] in Serum or Plasma 3.4 g/dL (low)
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-05-04 Bilirubin.total [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.2-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-05-04 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 212 U/L (high)
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-05-04 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 48 U/L (high)
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-05-04 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 41 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-05-04 INR in Platelet poor plasma by Coagulation assay 1
Reference 0.9-1.1
http://loinc.org · 6301-6
S 2026-05-04 Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 3.2 ng/mL
Reference <=8.3 ng/mL
http://loinc.org · 1834-1
S 2026-05-04 Cancer Ag 19-9 [Units/volume] in Serum or Plasma 412 U/mL (high)
Reference <=35 U/mL
http://loinc.org · 24108-3
S 2026-05-04 Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 8.6 ng/mL (high)
Reference Up to 3.0 ng/mL in non-smokers
http://loinc.org · 2039-6
S 2026-05-04 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-05-04 ECOG Performance Status score 1 http://loinc.org · 89247-1
S 2026-05-18 ECOG Performance Status score 1 http://loinc.org · 89247-1
S 2026-06-01 Leukocytes [#/volume] in Blood by Automated count 7.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-06-01 Neutrophils [#/volume] in Blood by Automated count 4.9 10*3/uL
Reference 1.8-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-06-01 Hemoglobin [Mass/volume] in Blood 12.2 g/dL (low)
Reference 13.2-17.1 g/dL
http://loinc.org · 718-7
S 2026-06-01 Platelets [#/volume] in Blood by Automated count 318 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-06-01 Sodium [Moles/volume] in Serum or Plasma 137 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-06-01 Potassium [Moles/volume] in Serum or Plasma 4.3 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-06-01 Creatinine [Mass/volume] in Serum or Plasma 0.84 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-06-01 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 102 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-06-01 Magnesium [Mass/volume] in Serum or Plasma 2 mg/dL
Reference 1.7-2.2 mg/dL
http://loinc.org · 19123-9
S 2026-06-01 Albumin [Mass/volume] in Serum or Plasma 3.4 g/dL (low)
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-06-01 Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.2-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-06-01 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 236 U/L (high)
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-06-01 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 52 U/L (high)
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-06-01 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 44 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-06-01 Thyrotropin [Units/volume] in Serum or Plasma 1.9 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-06-01 Cancer Ag 19-9 [Units/volume] in Serum or Plasma 498 U/mL (high)
Reference <=35 U/mL
http://loinc.org · 24108-3
S 2026-06-01 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 2026-06-01 ECOG Performance Status score 1 http://loinc.org · 89247-1
S 2026-08-03 Leukocytes [#/volume] in Blood by Automated count 4.6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-08-03 Neutrophils [#/volume] in Blood by Automated count 2.4 10*3/uL
Reference 1.8-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-08-03 Hemoglobin [Mass/volume] in Blood 10.9 g/dL (low)
Reference 13.2-17.1 g/dL
http://loinc.org · 718-7
S 2026-08-03 Platelets [#/volume] in Blood by Automated count 188 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-08-03 Sodium [Moles/volume] in Serum or Plasma 136 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-08-03 Potassium [Moles/volume] in Serum or Plasma 4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-08-03 Creatinine [Mass/volume] in Serum or Plasma 0.92 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-08-03 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 97 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-08-03 Glucose [Mass/volume] in Serum or Plasma 94 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-08-03 Magnesium [Mass/volume] in Serum or Plasma 1.7 mg/dL
Reference 1.7-2.2 mg/dL
http://loinc.org · 19123-9
S 2026-08-03 Albumin [Mass/volume] in Serum or Plasma 3.6 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-08-03 Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 mg/dL
Reference 0.2-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-08-03 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 158 U/L (high)
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-08-03 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 34 U/L
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-08-03 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-08-03 Thyrotropin [Units/volume] in Serum or Plasma 2.4 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-08-03 Cancer Ag 19-9 [Units/volume] in Serum or Plasma 168 U/mL (high)
Reference <=35 U/mL
http://loinc.org · 24108-3
S 2026-08-03 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-08-03 ECOG Performance Status score 1 http://loinc.org · 89247-1
S 2026-10-26 Leukocytes [#/volume] in Blood by Automated count 4.3 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-10-26 Neutrophils [#/volume] in Blood by Automated count 2.1 10*3/uL
Reference 1.8-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-10-26 Hemoglobin [Mass/volume] in Blood 10.7 g/dL (low)
Reference 13.2-17.1 g/dL
http://loinc.org · 718-7
S 2026-10-26 Platelets [#/volume] in Blood by Automated count 176 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-26 Sodium [Moles/volume] in Serum or Plasma 137 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-10-26 Potassium [Moles/volume] in Serum or Plasma 4.1 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-10-26 Creatinine [Mass/volume] in Serum or Plasma 0.95 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-10-26 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 93 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-10-26 Glucose [Mass/volume] in Serum or Plasma 96 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-10-26 Magnesium [Mass/volume] in Serum or Plasma 1.6 mg/dL (low)
Reference 1.7-2.2 mg/dL
http://loinc.org · 19123-9
S 2026-10-26 Albumin [Mass/volume] in Serum or Plasma 3.7 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-10-26 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.2-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-10-26 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 141 U/L (high)
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-10-26 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 U/L
Reference 10-40 U/L
http://loinc.org · 1920-8
S 2026-10-26 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-10-26 Thyrotropin [Units/volume] in Serum or Plasma 3.1 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 2026-10-26 Cancer Ag 19-9 [Units/volume] in Serum or Plasma 121 U/mL (high)
Reference <=35 U/mL
http://loinc.org · 24108-3
S 2026-10-26 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-10-26 ECOG Performance Status score 1 http://loinc.org · 89247-1
S 2026-09-02 Leukocytes [#/volume] in Blood by Automated count 3.9 10*3/uL (low)
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-09-02 Neutrophils [#/volume] in Blood by Automated count 1.6 10*3/uL (low)
Reference 1.8-7.7 10*3/uL
http://loinc.org · 751-8
S 2026-09-02 Hemoglobin [Mass/volume] in Blood 10.6 g/dL (low)
Reference 13.2-17.1 g/dL
http://loinc.org · 718-7
S 2026-09-02 Platelets [#/volume] in Blood by Automated count 162 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-09-21 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-05-04Body height165 cm8302-2S
2026-05-04Body weight61 kg29463-7S
2026-05-04Body mass index (BMI) [Ratio]22.4 kg/m239156-5S
2026-05-04Systolic blood pressure132 mm[Hg]8480-6S
2026-05-04Diastolic blood pressure84 mm[Hg]8462-4S
2026-05-04Heart rate88 /min8867-4S
2026-05-04Respiratory rate16 /min9279-1S
2026-05-04Body temperature36.9 Cel8310-5S
2026-05-04Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-05-18Body height165 cm8302-2S
2026-05-18Body weight60.6 kg29463-7S
2026-05-18Body mass index (BMI) [Ratio]22.3 kg/m239156-5S
2026-05-18Systolic blood pressure128 mm[Hg]8480-6S
2026-05-18Diastolic blood pressure82 mm[Hg]8462-4S
2026-05-18Heart rate86 /min8867-4S
2026-05-18Respiratory rate16 /min9279-1S
2026-05-18Body temperature36.8 Cel8310-5S
2026-05-18Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-06-01Body height165 cm8302-2S
2026-06-01Body weight60 kg29463-7S
2026-06-01Body mass index (BMI) [Ratio]22 kg/m239156-5S
2026-06-01Systolic blood pressure126 mm[Hg]8480-6S
2026-06-01Diastolic blood pressure80 mm[Hg]8462-4S
2026-06-01Heart rate84 /min8867-4S
2026-06-01Respiratory rate16 /min9279-1S
2026-06-01Body temperature36.7 Cel8310-5S
2026-06-01Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-08-03Body height165 cm8302-2S
2026-08-03Body weight59.2 kg29463-7S
2026-08-03Body mass index (BMI) [Ratio]21.7 kg/m239156-5S
2026-08-03Systolic blood pressure122 mm[Hg]8480-6S
2026-08-03Diastolic blood pressure78 mm[Hg]8462-4S
2026-08-03Heart rate82 /min8867-4S
2026-08-03Respiratory rate16 /min9279-1S
2026-08-03Body temperature36.6 Cel8310-5S
2026-08-03Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-10-26Body height165 cm8302-2S
2026-10-26Body weight59.6 kg29463-7S
2026-10-26Body mass index (BMI) [Ratio]21.9 kg/m239156-5S
2026-10-26Systolic blood pressure124 mm[Hg]8480-6S
2026-10-26Diastolic blood pressure78 mm[Hg]8462-4S
2026-10-26Heart rate80 /min8867-4S
2026-10-26Respiratory rate16 /min9279-1S
2026-10-26Body temperature36.6 Cel8310-5S
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-09-02Body height165 cm8302-2S
2026-09-02Body weight59 kg29463-7S
2026-09-02Body mass index (BMI) [Ratio]21.7 kg/m239156-5S
2026-09-02Systolic blood pressure120 mm[Hg]8480-6S
2026-09-02Diastolic blood pressure76 mm[Hg]8462-4S
2026-09-02Heart rate90 /min8867-4S
2026-09-02Respiratory rate16 /min9279-1S
2026-09-02Body temperature37.4 Cel8310-5S
2026-09-02Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-09-21Body height165 cm8302-2S
2026-09-21Body weight59.4 kg29463-7S
2026-09-21Body mass index (BMI) [Ratio]21.8 kg/m239156-5S
2026-09-21Systolic blood pressure122 mm[Hg]8480-6S
2026-09-21Diastolic blood pressure76 mm[Hg]8462-4S
2026-09-21Heart rate80 /min8867-4S
2026-09-21Respiratory rate16 /min9279-1S
2026-09-21Body temperature36.6 Cel8310-5S
2026-09-21Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Tissue diagnosis and complete staging within four weeks of the first visit2026-06-01completedBiopsy diagnosis in nine days and staging complete by laparoscopy in about three and a half weeks
Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1)2026-10-26completedAche 0 to 2 of 10 on acetaminophen as needed; ECOG 1 throughout
Weight held within 2 kg of the weight at the start of treatment2026-10-26completed60.0 kg at cycle 1 and 59.6 kg at cycle 8
Goals of care and a health care agent documented, and revisited as treatment changes2026-09-21completedAgent named and goals recorded with palliative care and at the preventive visit
Complete first-line chemoimmunotherapy without grade 3 or higher toxicity2026-10-26activeSeven cycles given by the last visit with grade 1 toxicity only; the eighth started that day

Interventions

InterventionStatusGuideline
Work-up of the liver mass: multiphase contrast CT of the liver with CT of the chest, abdomen and pelvis; MRI of the liver with MRCP if CT does not settle the origin; alpha-fetoprotein, CA 19-9 and CEA; hepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody; liver function with Child-Pugh and ALBI scoring; and image-guided core biopsy, because a mass in a liver without cirrhosis cannot be diagnosed by imaging alonecompletedGL-AASLD-HCC-2023, GL-NCCN-BIL-2026
Medical oncology consultation for a solid liver mass with weight loss: diagnosis, staging, multidisciplinary tumor board review, and treatmentcompletedGL-NCCN-BIL-2026, GL-AASLD-HCC-2023
Symptom care during the work-up: acetaminophen up to 3,000 mg a day, small frequent meals with a dietitian's advice, weight at every visit, and a same-day call for jaundice, fever, vomiting, dark urine or worse pain; results shared with him in full as they arrive, by one coordinating cliniciancompletedGL-NCCN-BIL-2026
Staging laparoscopy before any attempt at resection, with biopsy of any peritoneal disease and an implanted port under the same anesthetic; if no metastases, extended cholecystectomy with resection of liver segments IVb and V and portal lymphadenectomy; comprehensive genomic profiling of the biopsy tissue (HER2, mismatch repair and microsatellite status, BRAF, FGFR2, IDH1, NTRK, RET, KRAS, tumor mutational burden)completedGL-NCCN-BIL-2026
Hepatitis B reactivation monitoring for resolved infection (surface antigen negative, core antibody positive, HBV DNA undetectable): HBV DNA and ALT every 3 months during treatment and for at least 6 to 12 months after, with entecavir started promptly if HBV DNA becomes detectable or surface antigen reappearscompletedGL-ASCO-HBV-2020
First-line systemic therapy for stage IVB gallbladder adenocarcinoma: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg on day 1 every 21 days for up to 8 cycles, then durvalumab 1,500 mg every 4 weeks until progression or unacceptable toxicity; blood count, creatinine, magnesium and liver tests before each dose; TSH every cycle; CA 19-9 each cycle; CT of the chest, abdomen and pelvis every 2 to 3 months; teaching on immune-related side effects; ondansetron at homecompletedGL-NCCN-BIL-2026, GL-TOPAZ1-2022, GL-ASCO-IRAE-2021
Specialist palliative care alongside cancer treatment from the diagnosis of advanced disease: symptoms, nutrition, coping, goals of care, a health care agent, and a family meeting if and when he choosescompletedGL-ASCO-PALL-2017
Magnesium oxide 400 mg by mouth daily for cisplatin-related low magnesium, rechecked with each dose; durvalumab maintenance every 4 weeks after the eighth cycle, with restaging CT every 2 to 3 monthscompletedGL-NCCN-BIL-2026, GL-TOPAZ1-2022

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Barth RF, Chen J. What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death Chinese Journal of Cancer 2016;35(1):81 (PMID 27586157) scholarly
SRC-0002 Introduction to the Museum of Dr. Sun Yat-sen; Sun Yat-sen biography Museum of Dr. Sun Yat-sen (Cuiheng) biography
SRC-0003 Chow YYN. From medicine to politics (Dr Sun Yat-sen Oration) The Hong Kong Practitioner 2007;29(7), Hong Kong College of Family Physicians scholarly
SRC-0004 Sun Yat-sen chronology Museum of Dr. Sun Yat-sen (Cuiheng) biography
SRC-0005 Liu Ruiheng Tianjin University biography
SRC-0006 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the liver-mass work-up in a non-cirrhotic liver (biopsy rather than imaging criteria), the gallbladder primary, the staging laparoscopy, gemcitabine, cisplatin and durvalumab dosing and monitoring, hepatitis B monitoring rather than prophylaxis for resolved infection, and the timing of palliative care.
provenance reviewnot_startedBarth and Chen 2016 (PMC5009495), the Museum of Dr. Sun Yat-sen biography and chronology, Chow 2007 (The Hong Kong Practitioner), and the Tianjin University biography of Liu Ruiheng logged. The liver cancer and gallbladder cancer accounts are both recorded as R claims.
safe messaging reviewnot_startedA national founding figure; the modern episode adds no claim about his real health beyond the cited sources, his hepatitis B serology is labeled synthetic, and no decision or statement is attributed to his wife or other real people. His death is recorded as history only.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.